Загрузка...
Nivolumab in children and young adults with relapsed/refractory solid tumors (ADVL1412): A Phase 1 / 2 Trial
BACKGROUND: Immune checkpoint inhibitors targeting PD-1 have demonstrated clinical benefit in adults with cancer, but experience is limited in children. We conducted a Phase 1/2 study of nivolumab, a PD-1 blocking monoclonal antibody, to determine its safety, pharmacokinetics, and efficacy in childr...
Сохранить в:
| Опубликовано в: : | Lancet Oncol |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7255545/ https://ncbi.nlm.nih.gov/pubmed/32192573 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30023-1 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|